UbiVac
PORTLAND, Oregon, United States · Biotechnology, Healthcare
UbiVac has unique and disruptive immune educating and activating vaccine technology. UbiVac’s lead agent, DPV-001, contains the newly discovered non-mutated shared cancer neoantigens and more than 300 antigens for the majority of patients with adenocarcinoma or squamous cell cancers. Due to its unique platform vaccine technology, novel targets are being discovered that might be used for ADC, CAR-T
Key facts
- Headquarters
- PORTLAND, Oregon, United States
- Employees
- 14
- Industries
- Biotechnology, Healthcare
- Status
- Private
- Website
- ubivac.com
- Company page
Recent activity at UbiVac
- : UBIVAC
- : UBIVAC
- : UBIVAC
- : UBIVAC
- : UBIVAC
- : UBIVAC, INC.
- : UBIVAC, LLC
UbiVac funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $80K |
| Mar 2025 | Pre-Seed | $35K |
| Jun 2024 | Pre-Seed | $50K |
| Nov 2023 | Pre-Seed | $100K |
| Apr 2022 | Venture | $250K |
Leadership
- Bernard A. Fox, Founder
- Bernie Fox, Chief Financial Officer
- Hong-Ming Ph.D, Executive Officer
- Bernard Ph.D, Executive Officer
- Bernard MBA, Executive Officer
Verified email and direct lines for UbiVac’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
UbiVac files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to UbiVac
- Akadeum Life Sciences · Biotechnology, Healthcare
- MetaVia · Biotechnology, Healthcare
- HeartSciences · Biotechnology, Healthcare
- Glucotrack · Biotechnology, Healthcare
- NEXTSTEP ROBOTICS · Biotechnology, Healthcare
About UbiVac: questions and answers
What does UbiVac do?
UbiVac has unique and disruptive immune educating and activating vaccine technology. UbiVac’s lead agent, DPV-001, contains the newly discovered non-mutated shared cancer neoantigens and more than 300 antigens for the majority of patients with adenocarcinoma or squamous cell cancers. Due to its unique platform vaccine technology, novel targets are being discovered that might be used for ADC, CAR-T
Where is UbiVac headquartered?
UbiVac is headquartered in PORTLAND, Oregon, United States.
How many employees does UbiVac have?
UbiVac has about 14 employees.
Has UbiVac raised funding?
Yes. Fundz has recorded 5 funding events for UbiVac. The most recent, $80K, was in Aug 2026.
Who leads UbiVac?
Bernard A. Fox is a Founder at UbiVac.
What is the latest news on UbiVac?
On Aug 27, 2026, UBIVAC
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy